Fabio C.
- Country
- Italy
- Department
- Oncology Department
Research Overview
- Comparative Evaluation of Giredestrant and Triptorelin Versus Anastrozole and Triptorelin in Premenopausal ER-Positive/HER2-Negative Early Breast Cancer
- Phase II Study on Maintenance Therapy with Trastuzumab and Pertuzumab Post-Trastuzumab Deruxtecan in HER2-Positive Unresectable Metastatic Breast Cancer
- Phase 3 Randomized Study of DB-1303 Versus Investigator's Choice Chemotherapy in HER2-low, HR+ Metastatic Breast Cancer Post-Endocrine Therapy
Data & Insights
Has run more than one trial at 66 of 197 partner sites.
Specializations
Thoracic Oncology
Clinical research in non-small cell lung cancer and small cell lung cancer is a central area of interest, with attention to advanced, resectable, and biomarker-defined disease settings.
- Advanced NSCLC
- Resectable lung cancer
- Relapsed SCLC
- Biomarker-selected lung cancer
Additional activity includes studies in pleural mesothelioma and other thoracic malignancies, reflecting a strong therapeutic focus on pulmonary and pleural cancer care.
Breast Cancer and Hormone-Driven Malignancies
The investigator is involved in research on hormone receptor-positive and HER2-negative breast cancer, as well as HER2-positive and HER2-low metastatic breast cancer, spanning early and advanced disease.
- ER-positive/HER2-negative breast cancer
- HER2-positive metastatic breast cancer
- HER2-low breast cancer
- ESR1-mutated advanced breast cancer
Research also extends to endocrine-resistant disease and premenopausal breast cancer, highlighting interest in targeted endocrine and antibody-based treatment strategies.
Genitourinary Oncology
Another major focus is prostate cancer, including biochemically recurrent, intermediate-risk, and metastatic castration-resistant prostate cancer, with emphasis on disease control in both localized and advanced settings.
- Prostate cancer recurrence
- Metastatic castration-resistant prostate cancer
- Bladder cancer with FGFR alterations
- Urothelial carcinoma
Work in bladder cancer and urothelial carcinoma includes high-risk and non-muscle-invasive disease, indicating sustained involvement in genitourinary oncology.
Gastrointestinal Oncology
Clinical trial activity includes colorectal cancer, gastric and gastroesophageal junction adenocarcinoma, and esophageal squamous cell carcinoma, covering both resected and metastatic disease.
- Metastatic colorectal cancer
- Resected colon cancer
- Gastric and GEJ adenocarcinoma
- Esophageal squamous cell carcinoma
Research also involves minimal residual disease and circulating tumor DNA-guided treatment concepts in gastrointestinal malignancies.
Sarcoma, Bladder Cancer, and Cardiometabolic Disease
The investigator’s portfolio also includes soft tissue sarcoma subtypes such as dedifferentiated liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma, alongside selected studies in bladder cancer and non-oncologic disease areas.
- Dedifferentiated liposarcoma
- Leiomyosarcoma
- Undifferentiated pleomorphic sarcoma
- Heart failure and acute coronary syndromes
Additional involvement includes heart failure, acute myocardial infarction, atrial fibrillation, and neovascular age-related macular degeneration, broadening the therapeutic scope beyond oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.